In transfused patients with aplastic anemia, incidence of graft rejection remains significant. Seventeen transfused patients with severe aplastic anemia received BMT from HLA-identical sibling donors after conditioning with cyclophosphamide (CY, 50 mg/kg/day for 4 days) plus total lymphoid irradiation (TLI, 750 cGy in a single dose). For graft-versus-host disease (GVHD) prophylaxis one patient received methotrexate, five patients received CsA and 11 received CsA in association with methylprednisolone. All patients had sustained engraftment. The actuarial survival of patients was 76% with a median follow-up for surviving patients of 11 years (range 0.3-14.5 years). The incidence of grade II-III acute GVHD was 24%, and chronic GVHD 35%. Median Karnofsky score of surviving patients is 100 (range 90-100). Only one patient developed interstitial pneumonia. None of the patients has developed a malignancy after BMT. The role of limited field irradiation in development of malignant neoplasms after BMT for aplastic anemia is discussed. We conclude that a conditioning regimen using CY ؉ TLI in sensitized aplastic anemia patients results in a high survival rate on longterm follow-up. Keywords: bone marrow transplantation; severe aplastic anemia; total lymphoid irradiation Bone marrow transplantation from an HLA-identical related donor has been established as a highly effective treatment for patients with severe aplastic anemia, with long-term survival in 60-90% of patients.
transplantation for aplastic anemia, whereas incidence of graft rejection remains significant, especially in patients who have been previously transfused. Graft failure occurs in 5% to 30% of patients. 3, 4 Several factors such as adding radiation or antithymocyte globulin to cyclophosphamide for pretransplant conditioning, performing BMT prior to transfusion or adding buffy coat cells to the graft, have reduced the incidence of graft failure. 2, [5] [6] [7] In 1980, Ramsay et al 5 first reported a new conditioning regimen using total lymphoid irradiation combined with cyclophosphamide (CY ϩ TLI) for high-risk group patients with aplastic anemia which resulted in a lower incidence of graft rejection and graft-versus-host disease. Other studies have also reported the low rejection rate after BMT using CY ϩ TLI as conditioning for patients with aplastic anemia. 8, 9 Since the proportion of long-term survivors after transplant is increasing, the late complications of transplant, especially post-BMT neoplasms are emerging as a serious problem. 10 In this retrospective study, we report our experience of bone marrow transplantation for 17 consecutive transfused patients with severe aplastic anemia after conditioning with CY ϩ TLI and discuss the role of limited field irradiation in the development of malignant neoplasms following BMT for aplastic anemia.
Patients and methods

Patients
Between January 1980 and July 1998, 31 patients received BMT for severe aplastic anemia at the BMT Center of Pesaro. Eight patients who received BMT from HLA-identical sibling donors after conditioning with cyclophosphamide alone, five patients who received BMT from mismatched related donors and one patient who received a second BMT for rejection after conditioning with CY alone were excluded from analyses. The last patient received a second BMT from the same HLA-identical sibling after conditioning with CY ϩ TLI and had sustained engraftment. This study was restricted to 17 patients (10 males and seven females) with median age of 20 years (range 4-42 years) who received BMT from HLA-identical sibling donors after conditioning with CY ϩ TLI from April 1984 to July 1998 with a minimum follow-up of 0.3 years and maximum of 14.5 years. There were five patients р16 years old and 12 patients Ͼ16 years old. All but one surviving patient had survived a minimum of 7 years after BMT. Pretransplant recipient and donor characteristics are presented in Table  1 . Severe aplastic anemia was diagnosed by standard criteria. 11 Aplastic anemia was considered very severe if it met the criteria for severe disease and the ANC was less than 0.2 ϫ 10 9 /l. All patients were transfused and all but one received more than five transfusions. Patients or their legal guardians signed informed consent. All but four patients had received immunosuppressive therapy prior to BMT and failed to respond.
Donors
All donors were HLA-A, -B, -DR identical siblings. The results of bidirectional mixed lymphocyte culture carried out according to standard methods were negative in all cases. The median age was 22 years (range 8-45 years), and nine donors were male and eight were female.
Conditioning regimen and GVHD prophylaxis
Patients were prepared for transplantation with cyclophosphamide (CY), 50 mg/kg/day i.v. (day Ϫ6 to day Ϫ3), and total lymphoid irradiation (TLI) (day Ϫ1). The dose of radiation was 750 cGy 5 administered at 25 cGy/min in a single dose through anterior and posterior fields using a 10 MV Table 1 Characteristics of patients, donors and therapy
Characteristics Value
Median patient age (range), years 20 (4-42) 8 /kg). The median interval from diagnosis to transplant was 3 months (range 1-12 months), and the median number of transfusions was six units (range 3-55 units) ( Table 1) .
For GVHD prophylaxis one patient received MTX only, five patients received CsA only and 11 patients received CsA in association with low dose (0.5 mg/kg/day) methylprednisolone (MP). From day 60, the dose of CsA was tapered 5% every 2 weeks and discontinued by day 365 if no signs of chronic GVHD were present. Acute and chronic GVHD were diagnosed according to the Seattle criteria. 12 Patients with extensive chronic GVHD received methylprednisolone, azathioprine and/or CsA.
Supportive care
All patients were maintained in strict isolation in single rooms with positive-pressure HEPA-filtered air, received a low-bacterial diet and oral broad-spectrum nonabsorbable antibiotics. Prophylactic broad-spectrum system antibiotics (a semisynthetic penicillin or a third-generation cephalosporin and aminoglycoside), were begun on day Ϫ1 and continued until the granulocyte level exceeded 0.5 ϫ 10 9 /l and the patient was afebrile. From 1987 all patients received i.v. amphotericin B (0.3 mg/kg/day) as antifungal prophylaxis beginning on day ϩ8. Most patients received i.v. immune globulin. All patients were given acyclovir 15 mg/kg/day as herpes viruses prophylaxis from day Ϫ1 to day 60. All blood products administered were irradiated to 30 Gy.
Statistical analysis
The probability of survival was estimated using the method of Kaplan and Meier. 13 The Statistix statistical package 14 was used to examine possible relationship for the pre-BMT variables (age, sex mismatch, cell dose, pretransplant transfusions, interval from diagnosis to transplant, severity of disease) and survival, and to determine the time to engraftment.
Results
Engraftment and survival characteristics
All patients had sustained engraftment. The median times for granulocyte Ͼ0. The actuarial survival of patients was 76% (95% confidence interval: 50% to 93%) (Figure 1 ) with a median follow-up for surviving patients of 11 years (range 0.3-14.5 years). Univariate analyses were performed to assess the influence of pretransplant patient and donor characteristics on survival. No significant association was found when age, sex, severity of aplasia, interval from diagnosis to transplant, number of pretransplant transfusions and marrow cell dose were considered (probably due to the small numbers of patients; data not shown).
Four of 17 patients died. The latest death in this series occurred at 20 months following BMT. The causes of death were hemorrhage with or without septicemia (two patients) interstitial pneumonia (one patient) and fungal sepsis (one patient).
GVHD
Four out of 17 patients (24%) developed grade II-III acute GVHD. The incidence of extensive chronic GVHD was 35%. All six patients with extensive chronic GVHD received immunosuppressive therapy (steroids, CsA and/or azathioprine) and four of these have experienced complete resolution of chronic GVHD and are no longer receiving immunosuppressive therapy. One patient died with chronic GVHD. One patient is receiving tapering steroid therapy. Median Karnofsky score of surviving patients is 100 (range 90-100). Only one patient developed interstitial pneumonia.
In this series, thyroid function (T3, T4, FT3, FT4 and TSH) was studied in 11 out of 13 patients surviving after transplant. Only one patient had thyroid dysfunction (low levels of FT3, FT4 and TSH) 3 months after transplant. In the other 10 patients thyroid function studies at Ͼ7 years following transplantation were normal.
All surviving pediatric patients have normal growth. None of the patients has developed a malignancy after BMT. 
Discussion
There were three findings in this study. First, we showed that conditioning with CY ϩ TLI gives a 14.5 year actuarial survival of 76% in a series of 17 consecutive, transfused patients with severe aplastic anemia who received BMT in a single center. These results are comparable with other published data using limited field irradiation for conditioning. 9, 10, 15, 16 All our patients were transfused. Transfusions increase the risk of sensitization and subsequent graft rejection in patients with severe aplastic anemia following BMT. 17 In a recent Seattle study 2 in a large cohort of patients, the actuarial survival at 15 years after conditioning with CY or CY ϩ ALG was significantly lower in patients who received transfusions (63%) compared with patients who did not (81%). Although the number of patients is small, survival rate in our transfused patients, after conditioning with CY ϩ TLI, was higher than for transfused patients conditioned with CY ϩ ALG. Pneumonia was infrequent in our series, probably due to lung shielding.
The second finding is that no patient in our study experienced rejection. Despite increased survival after BMT due to reduced early mortality and decreased GVHD, the risk of graft failure has not changed over the last 15 years. 18 Factors which may contribute to graft rejection include previous transfusions, marrow cell dose infused, type of immunosuppression used, T cell depletion and addition of irradiation or ATG to the pretransplant conditioning regimen. 3 In a recent study from Seattle the rejection rate in transfused patients was 22% compared with 10% in nontransfused patients. 19 The higher sustained engraftment rate and absence of rejection in our transfused patients is probably the result of increased immunosuppression with TLI, which was first demonstrated in animal models. 20 This observation is consistent with previous reports which have shown that conditioning regimens containing either TBI or limited field irradiation resulted in a significantly lower rate of graft failure 5,9,15 as compared to those containing cyclophosphamide alone or CY ϩ ALG without radiation. 4 It has been suggested that the incidence of GVHD is higher in patients who receive conditioning which includes irradiation than in that not including irradiation. 8 In our patients the incidence of acute GVHD was lower, while the incidence of chronic GVHD was elevated. This slightly elevated incidence of chronic GVHD was probably related not to the irradiation itself, but probably to GVHD prophylaxis with CsA and methylprednisolone as was previously demonstrated in our patients with thalassemia. 21 In one study 43% of patients at Ͼ2 years following transplantation for aplastic anemia after conditioning with CY ϩ TLI had chemical evidence of hypothyroidism. 15 In our series only one out of 11 patients studied developed thyroid dysfunction. This lower incidence of thyroid dysfunction is probably the result of shielding of the thyroid gland.
The third finding in our series is that no patient developed a malignancy during a long follow-up period (up to 14.5 years). In the present study all but one of the surviving patients had survived у7 years (median 11.5 years, range 7-14.5 years) after BMT. The role of TLI in the increased risk of malignancies after BMT for aplastic anemia is controversial. The French study first reported an increased incidence of malignant solid tumors in 107 patients given marrow grafts for severe aplastic anemia after conditioning with CY and 6.0 Gy thoracoabdominal irradiation. 8 The cumulative incidence of secondary malignancies at 8 years was 22%. 22 In a recent study the Seattle group and the aforementioned French group reported their combined results to reassess the risk factors for developing post-transplant malignancies after transplantation for aplastic anemia and Fanconi anemia. 23 In this study multivariate analysis found only two factors (azathioprine therapy and the diagnosis of Fanconi anemia) that were associated with development of malignancies, while irradiation was a significant factor only if azathioprine was not included in the analysis. To date, however, the results of the French study have not been confirmed by other single center experiences using a conditioning regimen with CY ϩ TLI for aplastic anemia. 9, 10, 24, 25 The Minnesota group, which has a large single center experience with a longer follow-up (median 9.6 years; range 0.9-18.1 years), has only observed one malignancy (B-lymphoproliferative disorder) in 150 patients who received BMT for aplastic anemia after conditioning with CY and 7.5 Gy TLI (103 patients), CY ϩ TBI (27 patients) and CY alone (27 patients). 10 Recently, Deeg et al 26 reported interesting results. Eleven patients (12%) among 212 patients with aplastic anemia who received transplants in Seattle (all but 15 patients received non-irradiation containing regimen for conditioning) developed solid tumors. The probability of developing a malignancy was highest (30% at 20 years) in patients with both acute and chronic GVHD and lowest (0%) in patients with acute, but without chronic GVHD. Obviously, the development of chronic GVHD and its treatment with azathioprine have an important impact on the development of post-BMT malignancies.
Unlike the situation with hematologic malignancies, patients with aplastic anemia do not experience a substantial risk of developing malignancies from mutagenic chemotherapy experienced before transplant. On the other hand, the underlying diagnosis (malignant disease) may also play an important role in the development of malignancy after BMT. Improvements in radiation practices might have minimized the negative effects of TLI. We therefore speculate that, apart from TLI, patients with aplastic anemia may have a lower risk of developing a malignancy after BMT as compared to patients who have undergone BMT for a hematological malignancy. This observation is consistent with the lower incidence of malignancies in our 775 patients who underwent BMT for nonmalignant disorders (thalassemia and sickle cell syndromes) and who were followed for up to 16 years. 27 However, the small sample size in the present series does not allow definitive conclusions.
In conclusion, we showed that bone marrow transplantation in transfused patients with severe aplastic anemia after conditioning with CY ϩ TLI provides good long-term survival. The question of malignancies after conditioning with TLI remains open. Controlled trials with a longer follow-up are necessary to determine if preparative regimens using CY ϩ TLI to enhance engraftment increases the risk of malignancies after transplantation for aplastic anemia.
